

# Watson Pharmaceuticals

[View the current Watson Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/10965-Watson+Pharmaceuticals.html)

(<http://www.bioportfolio.com/bi corporate/10965-Watson+Pharmaceuticals.html>)

## Contact Details:

**311 Bonnie Circle**

**Corona**

**CA**

**91720**

**United States of America**

Tel: (951) 493-5300

Fax:

Email:

Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets and distributes brand and generic pharmaceutical products. With one of the broadest product offerings in the U.S. generics industry and a track record of service excellence, Watson has earned a solid reputation as a reliable and low-cost provider of quality pharmaceutical products.

## Press Releases on Watson Pharmaceuticals:

[Transcept](#)

[Pharmaceuticals](#)

[Scheduled to Meet With](#)

23rd November,

Transcept

[FDA to Discuss](#)

2009

Pharmaceuticals, Inc.

[Intermezzo\(R\) Complete](#)

[Response Letter](#)

*POINT RICHMOND, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA)*

*Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy*

[NCCN Updates NHL](#)

[Guidelines to Incorporate](#)

23rd November,

National Comprehensive

[FDA Approvals of New](#)

2009

Cancer Network

[Treatment Options](#)

|                                                                                                                          |                     |                                 |                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Poniard Announces \$7.4 Million Financing</a>                                                                | 23rd November, 2009 | Poniard Pharmaceuticals         | SAN FRANCISCO, Nov. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals (Nasdaq: PARD) today announced the sale of 3,465,878 of its common shares to Azimuth Opportunity Ltd. for gross proceeds of   |
| <a href="#">Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman</a>                         | 23rd November, 2009 | Ligon Discovery, Inc.           | CAMBRIDGE, Mass., Nov. 23 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced the appointment |
| <a href="#">Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients</a> | 23rd November, 2009 | Cumberland Pharmaceuticals Inc. | NASHVILLE, Tenn., Nov. 23 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced positive new top-line results from a study evaluating the safety and efficacy of    |

## BioNews Results for Watson Pharmaceuticals



- [Watson Announces Presentation Time Change at Credit Suisse Healthcare Conference](#)  
*PharmiWeb: Nov 15 2009 3:25AM Matching: watson pharmaceuticals*
- [Cephalon settles suit over generic](#)  
*Daily Local News: Nov 15 2009 1:26AM Matching: watson pharmaceuticals*
- [Cephalon, Barr Settle Fentora Dispute](#)  
*PharmaceuticalProcessing: Nov 14 2009 5:24PM Matching: watson pharmaceuticals*
- [Cephalon Announces Deal With Barr To Settle Patent Infringement Suit - Update](#)  
*RTTNews.com: Nov 13 2009 3:53AM Matching: watson pharmaceuticals*
- [Cephalon, Barr settle Fentora dispute](#)  
*Rocky Mount Telegram: Nov 13 2009 3:09AM Matching: watson pharmaceuticals*
- [Cephalon, Barr settle Fentora dispute](#)  
*WCAX TV3: Nov 13 2009 2:22AM Matching: watson pharmaceuticals*
- [Cephalon, Barr settle Fentora dispute](#)  
*Wooster Daily Record: Nov 13 2009 1:33AM Matching: watson pharmaceuticals*
- [Cephalon, Barr Settle Fentora Dispute](#)  
*ABC News: Nov 12 2009 11:57PM Matching: watson pharmaceuticals*
- [Cephalon, Barr settle patent dispute over pain treatment Fentora](#)  
*San Francisco Examiner: Nov 12 2009 11:49PM Matching: watson pharmaceuticals*
- [Cephalon, Barr settle Fentora dispute](#)  
*Austin American Statesman: Nov 13 2009 9:29AM Matching: watson pharmaceuticals*

- [Cephalon, Barr settle patent infringement suit](#)  
*Yahoo! Malaysia: Nov 13 2009 2:29AM Matching: watson pharmaceuticals*
- [Cephalon, Barr settle Fentora dispute](#)  
*Seattle Times: Nov 12 2009 11:30PM Matching: watson pharmaceuticals*
- [Cephalon, Barr settle Fentora dispute](#)  
*Washington Post: Nov 12 2009 11:45PM Matching: watson pharmaceuticals*
- [Cephalon, Barr settle Fentora dispute](#)  
*Fox 19: Nov 12 2009 11:30PM Matching: watson pharmaceuticals*
- [Cephalon, Barr settle patent dispute over pain treatment Fentora](#)  
*Canadian Business Magazine: Nov 12 2009 11:27PM Matching: watson pharmaceuticals*

#### Watson Pharmaceuticals Clinical Trials:



- [Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients](#)

#### Watson Pharmaceuticals Patents:



- 7338667- [Pharmaceutical formulation](#)
- 6180133- [Antioxidant composition for topical/transdermal prevention and treatment of wrinkles](#)
- 6210699- [Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity](#)
- 6365178- [Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions](#)
- 6544553- [Dosage forms and methods for oral delivery of progesterone](#)
- 6583129- [Administration of non-oral androgenic steroids to women](#)
- 6585963- [Nail compositions and methods of administering same](#)
- 6630166- [Compositions for conjugated estrogens and associated methods](#)
- 6693083- [Conjugates targeted to the interleukin-2 receptor](#)
- 6727401- [Pressure sensitive adhesive matrix patch for the treatment of onychomycosis](#)
- 6730318- [Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties](#)
- 6743441- [Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy](#)
- 6866865- [Dosage forms and methods for oral delivery of progesterone](#)
- 7179483- [Compositions and methods for transdermal oxybutynin therapy](#)
- 7186706- [Administration of non-oral androgenic steroids to women](#)
- 6153223- [Stabilized pharmaceutical compositions](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

